

**Unaudited Financial Statements for the Year Ended 30th November 2022**

**for**

**Immunoclot Ltd**

**Contents of the Financial Statements  
for the Year Ended 30th November 2022**

	<b>Page</b>
<b>Balance Sheet</b>	<b>1</b>
<b>Notes to the Financial Statements</b>	<b>2</b>

**Balance Sheet**  
**30th November 2022**

	Notes	30.11.22 £	£	30.11.21 £	£
<b>FIXED ASSETS</b>					
Tangible assets	4		-		-
Investments	5		-	5,000	5,000
			-		
<b>CURRENT ASSETS</b>					
Debtors	6	50,324		50,546	
Cash at bank		1,841		2,501	
		52,165		53,047	
<b>CREDITORS</b>					
Amounts falling due within one year	7	6,204		5,223	
<b>NET CURRENT ASSETS</b>			45,961		47,824
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			45,961		52,824
<b>CAPITAL AND RESERVES</b>					
Called up share capital	8		99		99
Retained earnings			45,862		52,725
<b>SHAREHOLDERS' FUNDS</b>			45,961		52,824

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30th November 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 30th November 2022 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 12th April 2023 and were signed by:

Dr P R J Ames - Director

**Notes to the Financial Statements  
for the Year Ended 30th November 2022**

**1. COMPANY INFORMATION**

Immunoclot Ltd is a private company, limited by shares, registered in Not specified/Other. The company's registered number and registered office address are as below:

<b>Registered number:</b>	05279113
<b>Registered office:</b>	First Floor 49 Peter Street Manchester M2 3NG

The presentation currency of the financial statements is the Pound Sterling (£).

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Tangible Fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment loss.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following basis:

Fixtures and Fittings - 25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to the profit or loss.

**Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

**Going concern**

The company has received no income during the year due to IR35 regulation changes. However, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

**3. EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 1 (2021 - 1) .

Notes to the Financial Statements - continued  
for the Year Ended 30th November 2022

4. **TANGIBLE FIXED ASSETS**

	Fixtures and fittings £
<b>COST</b>	
At 1st December 2021 and 30th November 2022	<u>881</u>
<b>DEPRECIATION</b>	
At 1st December 2021 and 30th November 2022	<u>881</u>
<b>NET BOOK VALUE</b>	
At 30th November 2022	<u>-</u>
At 30th November 2021	<u>-</u>

5. **FIXED ASSET INVESTMENTS**

	Unlisted investments £
<b>COST</b>	
At 1st December 2021	5,000
Disposals	<u>(5,000)</u>
At 30th November 2022	<u>-</u>
<b>NET BOOK VALUE</b>	
At 30th November 2022	<u>-</u>
At 30th November 2021	<u>5,000</u>

Fixed asset investments in non-quoted companies are measured at market value less any provisions for impairment. Where a market value is not ascertainable, the fixed asset investments are measured at cost.

6. **DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	30.11.22 £	30.11.21 £
Other debtors	<u>50,324</u>	<u>50,546</u>

7. **CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	30.11.22 £	30.11.21 £
Directors' current accounts	6,204	4,629
Accrued expenses	<u>-</u>	<u>594</u>
	<u>6,204</u>	<u>5,223</u>

Notes to the Financial Statements - continued  
for the Year Ended 30th November 2022

8. **CALLED UP SHARE CAPITAL**

<b>Allotted, issued and fully paid:</b>				
<b>Number:</b>	<b>Class:</b>	<b>Nominal value:</b>	<b>30.11.22</b>	<b>30.11.21</b>
			<b>£</b>	<b>£</b>
50	Ordinary A	1	50	50
49	Ordinary B	1	49	49
			<u>99</u>	<u>99</u>

The Ordinary A shares confer on the holders the right to vote upon any resolution proposed at any general meeting of the company.

The Ordinary B shares do not confer on the holders the right to vote upon any resolution proposed at any general meeting of the company.

The A and B shares rank pari passu in respect of dividend and capital distribution rights.

9. **DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES**

The following advances and credits to a director subsisted during the years ended 30th November 2022 and 30th November 2021:

	<b>30.11.22</b>	<b>30.11.21</b>
	<b>£</b>	<b>£</b>
<b>Dr P R J Ames</b>		
Balance outstanding at start of year	(4,629)	(3,155)
Amounts repaid	(1,575)	(1,474)
Amounts written off	-	-
Amounts waived	-	-
Balance outstanding at end of year	<u>(6,204)</u>	<u>(4,629)</u>

The loan is repayable on demand and no interest was charged during the year.

10. **CONTROL**

The ultimate controlling party is Dr P Ames by virtue of his 100% holding of the voting share capital.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.